Migraine pharmacotherapy with oral triptans: a rational approach to clinical management. - Wikidata - wikimedia - TriplyDB

Migraine pharmacotherapy with oral triptans: a rational approach to clinical management.

Migraine pharmacotherapy with oral triptans: a rational approach to clinical management.

http://www.wikidata.org/entity/Q33938046

about

Eletriptan for the treatment of migraine in patients with previous poor response or tolerance to oral sumatriptan.Eletriptan.Pharmacoeconomic evidence and considerations for triptan treatment of migraine.Safety profile of the triptans.Does sumatriptan cross the blood-brain barrier in animals and man?The blood-brain barrier in migraine treatment.Adverse effects of medications commonly used in the treatment of migraine.Within-patient early versus delayed treatment of migraine attacks with almotriptan: the sooner the better.Basic Principles in the Management of Depression in Neurologic Disorders

P2860

Q34205990-1341244D-67B9-42F5-9707-CF98B70F92C2 Q34481786-74E1D79B-903A-4D7B-9052-BEE5CFBAC2AC Q34544706-4480C505-8A9C-4C2A-A119-7CFFEDBB82AE Q35194407-827C2E95-D758-464C-8E28-B4B861C0F28E Q36260908-90926793-0D4D-46F3-A54A-293BC6CF0C26 Q37252452-C99DBB75-FEDC-4595-8901-FF3CC8769BBD Q37600874-91C37FE1-C3CB-4A04-8BEC-E7920CCBA4F9 Q42676166-D2E4A6A0-B827-4304-9F4F-F13612D90878 Q57544818-CF333A58-ED00-4217-A502-A1C2422F4079

P2860

Migraine pharmacotherapy with oral triptans: a rational approach to clinical management.

http://www.wikidata.org/entity/Q33938046

description

2000 nî lūn-bûn

@nan

2000 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2000 թվականի մարտին հրատարակված գիտական հոդված

@hy

2000年の論文

@ja

2000年学术文章

@wuu

2000年学术文章

@zh-cn

2000年学术文章

@zh-hans

2000年学术文章

@zh-my

2000年学术文章

@zh-sg

2000年學術文章

@yue

name

Migraine pharmacotherapy with oral triptans: a rational approach to clinical management.

@ast

Migraine pharmacotherapy with oral triptans: a rational approach to clinical management.

@en

type

label

Migraine pharmacotherapy with oral triptans: a rational approach to clinical management.

@ast

Migraine pharmacotherapy with oral triptans: a rational approach to clinical management.

@en

prefLabel

Migraine pharmacotherapy with oral triptans: a rational approach to clinical management.

@ast

Migraine pharmacotherapy with oral triptans: a rational approach to clinical management.

@en

P1433

Q33938046-E551142C-53A0-4CB3-9733-402199AA5B98

P1476

Q33938046-983D93CE-C7FE-4A68-8043-75CC2D8FD541

P2093

Q33938046-02C3E1FA-C648-4959-9DFE-EF97FBEA82D6

Q33938046-B62289C3-43D3-4502-9384-4979C9044987

Q33938046-DA4E692B-320D-4874-91C5-3269CAEAD467

P2860

Q33938046-0AEF8121-290C-4862-8765-B399997203D3

Q33938046-0EBB87BB-C4BA-43C0-AEDA-F6C6ED71C70B

Q33938046-3DA4E5E9-4BD6-484C-9B2C-B810A9D089AD

Q33938046-44A8044A-DA3C-4588-9DA3-5DF360AFB90D

Q33938046-4B933C4B-BEA4-4F2E-8A68-D5E41765C6F8

Q33938046-5288A6B5-B855-40A7-B106-CAF6DEB7475B

Q33938046-545E6071-DE1D-44B9-9952-A3E964A2B756

Q33938046-62FCA055-E89D-4186-81B4-1C7DAFAE93B0

Q33938046-9F0424E7-7D21-4403-90D2-1C4E5E9C944D

Q33938046-A5C98414-C595-47E7-B314-FCCECCB73E79

P304

Q33938046-80FA6512-A734-4E2A-B037-C5D2F2171BD7

P31

Q33938046-38CA1C58-F243-4965-9221-F7B08420495D

P356

Q33938046-B4C39E28-0A52-4E70-944F-5D62EEE4E00B

P407

Q33938046-36A173AD-041E-4E03-963F-CCD231F813CB

P433

Q33938046-71CCC2E5-F302-4F13-B71E-35DE734FDB40

P478

Q33938046-E11DA9CB-95C5-4132-BBBB-8AE45FDCCA4E

P577

Q33938046-D7990BF2-C2E9-4F01-BE60-3B2271B63A11

P698

Q33938046-307C7C7B-1F00-4172-BF27-37F652E5CF65

P921

Q33938046-2EA71CB3-F362-4619-BE85-F50BDB0FDA39

Q33938046-E9C898F4-9591-4BAF-A10F-BC6F563DF7A5

P356

14656566.1.3.391

P1433

Expert Opinion on Pharmacotherapy

P1476

Migraine pharmacotherapy with oral triptans: a rational approach to clinical management.

@en

P2093

Millson DS

http://www.w3.org/2001/XMLSchema#string

Rapoport AM

http://www.w3.org/2001/XMLSchema#string

Tepper SJ

http://www.w3.org/2001/XMLSchema#string

P2860

The absolute bioavailability and metabolic disposition of the novel antimigraine compound zolmitriptan (311C90).

Oral rizatriptan versus oral sumatriptan: a direct comparative study in the acute treatment of migraine. Rizatriptan 030 Study Group.

Crossover comparison of rizatriptan 5 mg and 10 mg versus sumatriptan 25 mg and 50 mg in migraine. Rizatriptan Protocol 046 Study Group.

Efficacy and safety of rizatriptan wafer for the acute treatment of migraine. Rizatriptan Wafer Protocol 049 Study Group.

Early clinical experience with subcutaneous naratriptan in the acute treatment of migraine: a dose-ranging study.

Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, and 100 mg) in the acute treatment of migraine: defining the optimum doses of oral sumatriptan.

Optimizing the dose of zolmitriptan (Zomig, 311C90) for the acute treatment of migraine. A multicenter, double-blind, placebo-controlled, dose range-finding study. The 017 Clinical Trial Study Group.

Double-blind, placebo-controlled, dose-finding study of rizatriptan (MK-462) in the acute treatment of migraine.

Effects of the novel high-affinity 5-HT(1B/1D)-receptor ligand frovatriptan in human isolated basilar and coronary arteries.

Inhibition of trigeminal neurons by intravenous administration of the serotonin (5HT)1B/D receptor agonist zolmitriptan (311C90): are brain stem sites therapeutic target in migraine?

P304

391-404

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1517/14656566.1.3.391

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P577

2000-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11249525

http://www.w3.org/2001/XMLSchema#string

P921

migraine disorder

pharmacotherapy